Correlations between HIV-1 clades and HIV-1 antibody neutralization sensitivity: Significant for vaccine development?

Current HIV Research

Volumn 8, Issue 8, 2010, Pages 579-586

  van Gils, Marit J ^a   Schuitemaker, Hanneke ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Clades; HIV 1; Humoral immunity; Neutralizing antibodies; Serotypes; Vaccine

Indexed keywords

ANTIGEN; CROSS REACTING ANTIBODY; GLYCOPROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

AMINO ACID SEQUENCE; ARTICLE; CLADISTICS; DISEASE COURSE; DRUG DESIGN; DRUG SENSITIVITY; ERADICATION THERAPY; GENETIC VARIABILITY; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION CONTROL; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC);

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; GENETIC VARIATION; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, HUMORAL; NEUTRALIZATION TESTS;

EID: 78650876330     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016210794088254     Document Type: Article

References (74)

1. Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 2004; 10(8): 806-10.
2. Walker BD, Burton DR. Toward an AIDS vaccine. Science 2008; 320(5877): 760-4.
3. Burton DR, Desrosiers RC, Doms RW, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5(3): 233-6.
4. Labrijn AF, Poignard P, Raja A, et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003; 77(19): 10557-65.
5. Kwong PD, Doyle ML, Casper DJ, et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002; 420(6916): 678-82.
6. Aasa-Chapman MM, Hayman A, Newton P, et al. Development of the antibody response in acute HIV-1 infection. AIDS 2004; 18(3): 371-81.
7. Bunnik EM, Pisas L, van Nuenen AC, Schuitemaker H. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol 2008; 82(16): 7932-41.
8. Moore PL, Ranchobe N, Lambson BE, et al. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog 2009; 5(9): e1000598.
9. Rong R, Li B, Lynch RM, Haaland RE, et al. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog 2009; 5(9): e1000594.
10. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422(6929): 307-12.
11. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003; 100(7): 4144-9.
12. Li Y, Migueles SA, Welcher B, et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007; 13(9): 1032-4.
13. Sather DN, Armann J, Ching LK, et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 2009; 83(2): 757-69.
14. Euler Z, van Gils MJ, Bunnik EM, et al. Cross-reactive neutralizing humoral immunity does not protect from HIV-1 disease progression. J Infect Dis 2009; In press.
15. van Gils MJ, Euler Z, Schweighardt B, Wrin T, Schuitemaker H. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS 2009; 23(18): 2405-14.
16. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271: 1582-6.
17. Drake JW. Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci USA 1993; 90(9): 4171-5.
18. Barouch DH, Letvin NL. HIV escape from cytotoxic T lymphocytes: a potential hurdle for vaccines? Lancet 2004; 364(9428): 10-1.
19. Shankarappa R, Margolick JB, Gange SJ, et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999; 73(12): 10489-502.
20. Malim MH, Emerman M. HIV-1 sequence variation: drift, shift, and attenuation. Cell 2001; 104(4): 469-72.
21. Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science 2002; 296(5577): 2354-60.
22. Stebbing J, Moyle G. The clades of HIV: their origins and clinical significance. AIDS Rev 2003; 5(4): 205-13.
23. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004; AIDS 2006; 20(16): W13-W23.
24. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. The challenge of HIV-1 subtype diversity. N Engl J Med 2008; 358(15): 1590-602.
25. Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 2003; 51(2): 229-40.
26. McKnight A, asa-Chapman MM. Clade specific neutralising vaccines for HIV: an appropriate target? Curr HIV Res 2007; 5(6): 554-60.
27. Moore JP, Parren PW, Burton DR., Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J Virol 2001; 75(13): 5721-9.
28. Kostrikis LG, Cao Y, Ngai H, Moore JP, Ho DD. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol 1996; 70(1): 445-58.
29. Nyambi PN, Nkengasong J, Lewi P, et al. Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J Virol 1996; 70(9): 6235-43.
30. Weber J, Fenyo EM, Beddows S, Kaleebu P, Bjorndal A. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization. J Virol 1996; 70(11): 7827-32.
31. Seaman MS, Janes H, Hawkins N, et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 2010; 84(3): 1439-52.
32. Simek MD, Rida W, Priddy FH, et al. HIV-1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified Using a High Throughput Neutralization Assay Together with an Analytical Selection Algorithm. J Virol 2009; 83(14): 7337-48.
33. Brown BK, Wieczorek L, Sanders-Buell E, et al.Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 2008; 375(2): 529-38.
34. Binley JM, Wrin T, Korber B, et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004; 78(23): 13232-52.
35. Li M, Salazar-Gonzalez JF, Derdeyn CA, et al. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 2006; 80(23): 11776-90.
36. Mascola JR, Louder MK, Surman SR, et al.Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res Hum Retroviruses 1996; 12(14): 1319-28.
37. Binley JM, Lybarger EA, Crooks ET, et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 2008; 82(23): 11651-68.
38. van Gils MJ, Edo-Matas D, Schweighardt B, Wrin T, Schuitemaker H. High Prevalence of Neutralizing Activity against Multiple Unrelated HIV-1 Subtype B Variants in Sera from HIV-1 Subtype B Infected Individuals: Evidence for Subtype Specific Rather than Strain Specific Neutralizing Activity. J Gen Virol 2010; 91(01): 250-8.
39. Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target. Science 2009; 326(5950): 285-9.
40. Wu X, Zhou T, O'Dell S, Wyatt RT, Kwong PD, Mascola JR. Mechanism of HIV-1 Resistance to Monoclonal Antibody b12 that Effectively Targets the Site of CD4 Attachment. J Virol 2009; 83(21): 10892-907.
41. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, Kayman SC. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 2004; 78(10): 5205-15.
42. Rong R, Bibollet-Ruche F, Mulenga J, Allen S, Blackwell JL, Derdeyn CA. Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J Virol 2007; 81(3): 1350-9.
43. Sagar M, Wu X, Lee S, Overbaugh J. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 2006; 80(19): 9586-98.
44. Davis KL, Bibollet-Ruche F, Li H, et al. Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J Virol 2009; 83(3): 1240-59.
45. Gorny MK, Williams C, Volsky B, et al. Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1. J Virol 2006; 80(14): 6865-72.
46. Krachmarov CP, Honnen WJ, Kayman SC, Gorny MK, Zolla-Pazner S, Pinter A. Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1. J Virol 2006; 80(14): 7127-35.
47. Murphy G, Belda FJ, Pau CP, Clewley JP, Parry JV. Discrimination of subtype B and non-subtype B strains of human immunodeficiency virus type 1 by serotyping: correlation with genotyping. J Clin Microbiol 1999; 37(5): 1356-60.
48. Moore PL, Gray ES, Choge IA, et al. The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol 2008; 82(4): 1860-9.
49. Li B, Decker JM, Johnson RWB, et al. Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol 2006; 80(11): 5211-8.
50. Dreja H, O'Sullivan EM, Pade C, et al. Neutralisation activity in a geographically diverse East London cohort of HIV-1 infected patients: Clade C infection results in a stronger and broader humoral immune response than clade B infection. J Gen Virol 2010; 91(Pt 11): 2794-803.
51. Gnanakaran S, Lang D, Daniels M, Bhattacharya T, Derdeyn CA, Korber B. Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120. J Virol 2007; 81(9): 4886-91.
52. Diskin R, Marcovecchio PM, Bjorkman PJ. Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. Nat Struct Mol Biol 2010; 17(5): 608-13.
53. Wu Y, Yang ZY, Li Y, et al. Rational Design of Envelope Surface Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. Science 2010; In Press.
54. Piantadosi A, Panteleeff D, Blish CA, et al. HIV-1 neutralizing antibody breadth is affected by factors early in infection, but does not influence disease progression. J Virol 2009; 83(19): 10269-74.
55. Scheid JF, Mouquet H, Feldhahn N, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009; 458(7238): 636-40.
56. Doria-Rose NA, Klein RM, Manion MM, O'Dell S, Phogat A, Chakrabarti B, et al. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 2009; 83(1): 188-99.
57. Euler Z, van Gils MJ, Bunnik EM, et al. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis 2010; 201(7): 1045-53.
58. Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 2009; 15(8): 866-70.
59. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010; 10(1): 11-23.
60. Dhillon AK, Donners H, Pantophlet R, et al. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 2007; 81(12): 6548-62.
61. Sather DN, Stamatatos L. Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects. Vaccine 2010; 28(Suppl 2): B8-12.
62. Conley AJ, Gorny MK, Kessler JA, et al. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol 1994; 68(11): 6994-7000.
63. van Gils MJ, Bunnik EM, Burger JAJ, et al. Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors. J Virol 2010; 84(7): 3576-85.
64. Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Annu Rev Immunol 2010; 28: 413-44.
65. Mascola JR, Snyder SW, Weislow OS, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 1996; 173: 340-8.
66. Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005; 191(5): 666-77.
67. Cho MW, Kim YB, Lee MK, et al. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques. J Virol 2001; 75(5): 2224-34.
68. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N Engl J Med 2009; 361(23): 2209-20.
69. Forthal DN, Moog C. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS 2009; 4(5): 388-93.
70. Gao F, Scearce RM, Alam SM, et al. Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. Virology 2009; 394(1): 91-8.
71. Korber B, Gnanakaran S. The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. Curr Opin HIV AIDS 2009; 4(5): 408-17.
72. Kong WP, Wu L, Wallstrom TC, et al. Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol 2009; 83(5): 2201-15.
73. Corey L, McElrath MJ. HIV vaccines: mosaic approach to virus diversity. Nat Med 2010; 16(3): 268-70.
74. Leitner T, Korber B, Daniels M, Calef C, Foley B., HIV-1 Subtype and Circulating Recombinant Form (CRF) Reference Sequences, 2005. HIV Sequence Compendium 2005 2005; 41-8.